Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT05743036	TitleZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2023-02-24	Location California, United States Kansas, United States Texas, United States Australia Germany Hungary Italy Poland Spain	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, encorafenib, ZN-c3	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05759728	TitleA Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2023-03-08	Location Australia	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05714553	TitleNUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours	Phase Phase 1, Phase 2	Date Added 2023-02-06	Location United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Docetaxel, Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab	Tags MSI-H/ MMRd
NCT ID NCT05426005	TitleCadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer	Phase Phase 1, Phase 2	Date Added 2022-06-21	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Cadonilimab	Tags MSI-H/ MMRd
NCT ID NCT05653882	TitleA Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors	Phase Phase 1	Date Added 2022-12-16	Location California, United States Connecticut, United States Florida, United States Massachusetts, United States Michigan, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Tennessee, United States Virginia, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05464030	TitleAnti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)	Phase Phase 1	Date Added 2022-07-19	Location California, United States Rhode Island, United States Texas, United States Canada Japan Korea, Republic of Spain	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs M9140	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05198934	TitleSotorasib and Panitumumab Versus Investigator’s Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)	Phase Phase 3	Date Added 2022-01-20	Location Alabama, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia France Germany Greece Italy Japan Korea, Republic of Mexico Spain Taiwan United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05349890	TitlePersonalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)	Phase Phase 1	Date Added 2022-04-27	Location Oregon, United States	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs CDX-1140, Pembrolizumab, Keytruda	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05350917	TitleStudy of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy	Phase Phase 2	Date Added 2022-04-28	Location	Prior IO Allowed Yes	CRC-directed Yes	Status Not yet recruiting	Drugs Tislelizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05409417	TitleExploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status	Phase Phase 2	Date Added 2022-06-08	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Unknown status	Drugs Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX	Tags MSS/ MMRp

Showing 131 to 140 of 299 entries